Contact
searchSearch
HMP Global

Amyotrophic Lateral Sclerosis Topic Center

A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Declines Accelerated Approval for Novel ALS Drug
01/05/2024
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug...
01/05/2024
Neurology
Brain health
News
Environmental Pollutants Linked With Increased ALS Risk, Mortality
11/21/2023
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was...
11/21/2023
Neurology
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
News
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
07/18/2023
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help...
07/18/2023
Neurology
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
News
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
06/14/2023
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential...
06/14/2023
Neurology
A hand chooses a happy face with a neutral and unhappy face next to them
News
ALS Patients Evaluate Facial Expressions Differently, Even Without Cognitive Impairment
05/18/2023
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic...
05/18/2023
Neurology
News
FDA Advisory Committee Backs Accelerated Approval of Tofersen for SOD1-ALS
04/24/2023
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed...
04/24/2023
Neurology
A clock sits on a desk beside a pencil and scantron.
Quiz
Which gene mutation accounts for 20% of ALS cases?
03/27/2023
Time for a quick neurology quiz!
Time for a quick neurology quiz!
Time for a quick neurology quiz!
03/27/2023
Neurology
News
ALS Therapy Receives FDA Orphan Drug Designation
03/21/2023
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug...
03/21/2023
Neurology

News

A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Declines Accelerated Approval for Novel ALS Drug
01/05/2024
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug...
01/05/2024
Neurology
Brain health
News
Environmental Pollutants Linked With Increased ALS Risk, Mortality
11/21/2023
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was...
11/21/2023
Neurology
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
News
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
07/18/2023
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help...
07/18/2023
Neurology
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
News
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
06/14/2023
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential...
06/14/2023
Neurology
A hand chooses a happy face with a neutral and unhappy face next to them
News
ALS Patients Evaluate Facial Expressions Differently, Even Without Cognitive Impairment
05/18/2023
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic...
05/18/2023
Neurology
News
FDA Advisory Committee Backs Accelerated Approval of Tofersen for SOD1-ALS
04/24/2023
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed...
04/24/2023
Neurology
News
ALS Therapy Receives FDA Orphan Drug Designation
03/21/2023
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug...
03/21/2023
Neurology
News
Prototype Soft Robotic Wearable Restores Arm Function for ALS Patients, Hints at Future of Assistive Technology
03/16/2023
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable...
03/16/2023
Neurology
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use